Analyser av Elicera Therapeutics

Elicera Therapeutics: Postponing final reporting of ELC-100 study - Redeye

Redeye briefly comments on yesterday’s news that the final reporting of the ELC-100 study will be postponed.

Elicera Therapeutics Q1: Positive pattern emerging in CARMA trial - Redeye

Redeye returns with an updated view following Elicera’s Q1 report and encouraging data from the phase I/II CARMA study, evaluating ELC-301 i...

Redeye • 28 May 09:04

Elicera Therapeutics: Second complete response in CARMA study - Redeye

Redeye comments on the intriguing data from the phase I/II CARMA-study presented by Elicera this morning.

Redeye • 22 May 09:45

Elicera Therapeutics: All eyes on upcoming data - Redeye

Redeye provides a brief summary of Elicera’s Q1'25 report.

Redeye • 16 May 10:06

Elicera Therapeutics: Outcome of warrant program announced - Redeye

Redeye gives a short comment on the positive outcome of Elicera’s TO2 warrant program.

Redeye • 13 Mar 16:59

Elicera Therapeutics: Secures warrant program through a combination of guarantees and subscription commitments - Redeye

Redeye gives a short comment on today’s news that Elicera has secured 100% of the TO2 program.

Redeye • 26 Feb 07:19

Elicera Therapeutics Q4: Eventful 2025 ahead - Redeye

Redeye returns following Elicera's Q4 report and recent news in the company.

Redeye • 06 Feb 12:38

Elicera Therapeutics: On the right path - Redeye

Redeye revisits some assumptions related to financing and likelihood of approval following the progress with the CARMA study and the recent ...

Redeye • 28 Jan 11:00

Elicera Therapeutics: Promising first data from CARMA study - Redeye

Redeye gives an initial take on the first clinical results from the CARMA study with ELC-301.

Redeye • 21 Jan 15:52

Elicera Therapeutics: Receives orphan drug designation in the US for ELC-100 in pancreatic neuroendocrine tumors - Redeye

Redeye endorses today’s news that Elicera has received an orphan drug designation in the US for ELC-100 in pancreatic neuroendocrine tumors,...

Redeye • 13 Jan 15:31

Elicera Therapeutics Q3: CARMA study initiated - Redeye

Redeye returns following Elicera's Q3 report and recent news in the company.

Redeye • 29 Nov 2024 08:40

Elicera Therapeutics: First patient included in ELC-301 CARMA (phase I/II) study - Redeye

Redeye gives a brief comment on today’s news that the first patient has been included in the ELC-301 CARMA (I/IIa) study.

Redeye • 06 Nov 2024 07:04

Elicera Therapeutics: Tackling Tumour Heterogeneity - Redeye

Redeye initiates coverage of Elicera Therapeutics, a Swedish clinical-stage biotech company focusing on cell and gene therapies for cancer t...

Redeye • 17 Oct 2024 09:58

Elicera Therapeutics: Flaggskeppsprojekt får betydande finansiering - Carlsquare

Elicera har fått EU-stöd om 2,5 miljoner Euro för en fas I/II-studie med ELC-301, bolagets längst utvecklade cellterapiprojekt, inom blodcan...

Carlsquare • 02 Jun 2022 10:33

Elicera Therapeutics: Affärsutveckling i sikte - Carlsquare

Elicera anger ett mål om att träffa ett kommersiellt avtal för iTANK-teknologin i år.

Carlsquare • 27 Apr 2022 07:43

Elicera Therapeutics: Publicering kan ge ökad uppmärksamhet - Carlsquare

Forskargruppen bakom Elicera har fått en vetenskaplig artikel om iTANK-teknologin publicerad i Nature.

Carlsquare • 06 Apr 2022 09:00

Elicera Therapeutics: Nytt forskningsstöd och patentköp - Carlsquare

Elicera inleder utveckling av en automatiserad tillverkningsprocess för CAR T-cellterapi och har förvärvat patentet för ELC-100.

Carlsquare • 19 Jan 2022 10:09

Elicera Therapeutics: Cell Therapy Company Under the Radar - Carlsquare

Carlsquare Equity Research initiates coverage of Elicera Therapeutics and identifies a cancer research company with good potential.

Carlsquare • 20 Dec 2021 14:58

Elicera Therapeutics: Oupptäckt cellterapibolag inom hett område - Carlsquare

Carlsquare Equity Research inleder bevakning av Elicera Therapeutics och identifierar ett cancerforskningsföretag med god potential till upp...

Carlsquare • 13 Dec 2021 08:37